These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28559262)

  • 1. Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
    Dutta NK; Pinn ML; Karakousis PC
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
    Dutta NK; Pinn ML; Karakousis PC
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5567-9. PubMed ID: 24936590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
    Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
    Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
    Mourik BC; de Knegt GJ; Verbon A; Mouton JW; Bax HI; de Steenwinkel JEM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739784
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
    Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
    Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
    De Groote MA; Gruppo V; Woolhiser LK; Orme IM; Gilliland JC; Lenaerts AJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):731-8. PubMed ID: 22143517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
    De Groote MA; Gilliland JC; Wells CL; Brooks EJ; Woolhiser LK; Gruppo V; Peloquin CA; Orme IM; Lenaerts AJ
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1237-47. PubMed ID: 21135176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
    Dutta NK; Alsultan A; Gniadek TJ; Belchis DA; Pinn ML; Mdluli KE; Nuermberger EL; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3910-6. PubMed ID: 23733473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.
    Ahmad Z; Nuermberger EL; Tasneen R; Pinn ML; Williams KN; Peloquin CA; Grosset JH; Karakousis PC
    J Antimicrob Chemother; 2010 Apr; 65(4):729-34. PubMed ID: 20123722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.
    Skerry C; Pinn ML; Bruiners N; Pine R; Gennaro ML; Karakousis PC
    J Antimicrob Chemother; 2014 Sep; 69(9):2453-7. PubMed ID: 24855121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
    Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y
    J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.
    Williams KN; Brickner SJ; Stover CK; Zhu T; Ogden A; Tasneen R; Tyagi S; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2009 Aug; 180(4):371-6. PubMed ID: 19520903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.